Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 1 of 39 PageID #: 29236
`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`GENENTECH, INC.
`
`v.
`
`AMGEN INC.,
`
`
`
`C.A. No. 18-924-CFC
`
`
`
`
`
`
`Plaintiff,
`
`Defendant.
`
`
`
`
`
`
`
`DECLARATION OF DARALYN J. DURIE
`
`I, Daralyn J. Durie, Esq., declare as follows:
`
`1.
`
`I am an attorney at the law firm of Durie Tangri LLP, counsel to Plaintiff
`
`Genentech, Inc. in the above-captioned action. I respectfully submit this declaration for
`
`the purpose of transmitting certain documents filed in support of Plaintiffs’ Opening
`
`Brief in Support of its Motion for Sanctions.
`
`2.
`
`Attached as Exhibit 1 is a true and correct copy of a letter dated June 3,
`
`2019 from Andrew J. Danford regarding Amgen’s Production of Opinions of Counsel.
`
`3.
`
`Attached as Exhibit 2 is a true and correct copy of a letter dated June 11,
`
`2019 from Eamonn Gardner regarding Discovery regarding Opinions of Counsel.
`
`4.
`
`Attached as Exhibit 3 is a true and correct copy of the sealed June 18,
`
`2019 hearing transcript.
`
`5.
`
`Attached as Exhibit 4 is a true and correct copy of a Notice of Electronic
`
`Filing for D.I. 259 regarding Order granting Plaintiff’s Motion to Compel.
`
`6.
`
`Attached as Exhibit 5 is a true and correct copy of a Notice of Electronic
`
`Filing for D.I. 488 & D.I. 345 regarding Memorandum Order.
`
`
`ME1 31544790v.1
`
`PUBLIC VERSION FILED: October 4, 2019
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 2 of 39 PageID #: 29237
`
`
`
`7.
`
`Attached as Exhibit 6 is a true and correct copy of document
`
`AMGKAN03002837 - 03002856.
`
`8.
`
`Attached as Exhibit 7 is a true and correct copy of document
`
`AMGKAN03002583 - 03002612.
`
`9.
`
`Attached as Exhibit 8 is a true and correct copy of document
`
`AMGKAN02999058 - 02999097.
`
`10.
`
`Attached as Exhibit 9 is a true and correct copy of document
`
`AMGKAN02988860 – 02988899.
`
`11.
`
`Attached as Exhibit 10 is a true and correct copy of document
`
`AMGKAN02989139 - 02989225.
`
`12.
`
`Attached as Exhibit 11 is a true and correct copy of the September 17,
`
`2019 deposition transcript of Lois Kwasigroch.
`
`13.
`
`Attached as Exhibit 12 is a true and correct copy of the September 23,
`
`2019 deposition rough mini-transcript of Stuart Watt.
`
`14.
`
`Attached as Exhibit 13 is a true and correct copy of the September 10,
`
`2019 deposition transcript of Mark Izraelewicz.
`
`
`
`I declare under penalty of perjury that the foregoing is true and correct to the best
`
`of my knowledge.
`
`EXECUTED this 24th day of September, 2019.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/s/ Daralyn J. Durie
`Daralyn J. Durie
`
`
`
`
`
`
`
`ME1 31544790v.1
`
`2
`
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 3 of 39 PageID #: 29238
`Case 1:18—cv-00924-CFC Document 393 Filed 10/04/19 Page 3 of 39 PageID #: 29238
`
`EXHIBIT 1
`
`EXHIBIT 1
`
`

`

`
`
`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 4 of 39 PageID #: 29239
`
`
`
`June 3, 2019
`
`Michelle Rhyu
`Eamonn Gardner
`Susan Krumplitsch
`Daniel J. Knauss
`Orion Armon
`Benjamin Lin
`Lauren Krickl
`COOLEY LLP
`
`Andrew J. Danford
`
`+1 617 526 6806 (t)
`+1 617 526 5000 (f)
`andrew.danford@wilmerhale.com
`
`Re: Amgen’s Production of Opinions of Counsel
`
`Counsel,
`
`We have received Amgen’s May 31, 2019 production of two opinions of counsel:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`We were surprised by the timing of this production, given that fact discovery is about to
`close and Amgen has consistently asserted privilege over these matters, including during
`depositions that occurred last week immediately before Amgen chose to disclose these opinions.
`Amgen’s belated decision to waive privilege raises many new issues that will need to be addressed,
`and we are prejudiced by Amgen’s delay in disclosing these opinions until ten days before the
`close of fact discovery.
`
`As an initial matter, Amgen’s production of the opinion letters alone is insufficient. By
`producing these letters, Amgen has waived privilege as to the subject matter of these opinions.
`See In re EchoStar Commc’ns Corp., 448 F.3d 1294 (Fed. Cir. 2006) (waiver extends to “any
`attorney-client communications relating to the same subject matter”). Amgen should have
`produced all documents falling with the scope of Amgen’s privilege waiver at the time that it
`produced the opinion letters. Plaintiffs therefore expect that Amgen will immediately provide the
`following documents:
`
`1. All documents from and correspondence with
`
` regarding these opinions, including any files from opinion counsel and
`correspondence with opinion counsel;
`
`2. All underlying documents and drafts of the opinion letters; and
`
`
`
`
`
`
`
`
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 5 of 39 PageID #: 29240
`
`Michelle Rhyu
`June 3, 2019
`Page 2
`
`
`
`3. All documents relating to the subject matter of these opinion letters, including
`communications with and among any in-house counsel at Amgen, and any other
`opinions or advice of counsel given or received relating to the subject matter
`
`Also, as a subject matter waiver, Amgen’s waiver of privilege is not limited to this case.
`
`To the extent that Amgen has received opinions relating to the same subject matter in other
`litigations (e.g., in connection with C.A. 17-cv-1407-CFC), we expect that Amgen will provide
`those opinions to us, as well as any documents encompassed by Amgen’s privilege waiver. We
`also expect that Amgen will withdraw its privilege objections to (1) Plaintiffs’ Request for
`Production Nos. 36, 51, and 92; and (2) Plaintiffs’ 30(b)(6) Topic Nos. 21, 24, 25, 26, 36, 37, 55,
`and 56 in view of its waiver of privilege. To the extent that Amgen has clawed back documents
`relating to the subject matter of Amgen’s waiver (including with respect to Amgen’s label changes
`or efforts to design around the ’869 patent), we expect those documents to be produced to us again.
`
`To the extent that Amgen is withholding or redacting any documents relating to (1) the
`
`validity of U.S. Patent Nos. 6,627,196, 7,371,379, and 10,160,811 or (2) the validity and/or
`infringement of U.S. Patent No. 8,574,869, we expect that Amgen will provide a supplemental
`privilege log identifying all documents being withheld and/or redacted by Amgen through the
`present date so that we can evaluate the scope of Amgen’s privilege waiver. The privilege log
`should include all communications internal to Amgen, as well as with any outside counsel,
`including litigation counsel.
`
`Amgen’s waiver of privilege also affects the scope of the deposition discovery remaining
`in this case. Below are several deposition-related issues that we need to address:
`
`1. Please provide deposition dates for
` We also intend
`to take depositions of any in-house counsel at Amgen involved in obtaining these
`opinion letters;
`
`2. Amgen has previously asserted privilege and instructed its witnesses not to answer
`questions concerning the subject matter addressed in these opinion letters during
`the following depositions:
`
` Amgen’s waiver also affects the deposition testimony
`We intend to reopen those depositions now that Amgen has
`of
`waived privilege. Please provide their availability to be deposed;
`
`4. Please provide a designee on Plaintiffs’ Rule 30(b)(6) topic 84 relating to
`opinions of counsel; and
`
`
`
`
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 6 of 39 PageID #: 29241
`
`Michelle Rhyu
`June 3, 2019
`Page 3
`
`
`
`5. Given that Amgen has not completed its production of documents falling within
`the scope of its privilege waiver, we will hold open
`deposition until
`that production is complete.
`
`We appreciate your prompt attention to these matters. If Amgen will not be providing
`any of what we have outlined above, please let us know your availability on Tuesday, June 4,
`2019 to meet and confer.
`
`Best regards,
`
`Andrew J. Danford
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 7 of 39 PageID #: 29242
`Case 1:18—cv-00924-CFC Document 393 Filed 10/04/19 Page 7 of 39 PageID #: 29242
`
`EXHIBIT 2
`
`EXHIBIT 2
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 8 of 39 PageID #: 29243
`CONTAINS CONFIDENTIAL INFORMATION SUBJECT TO PROTECTIVE ORDER
`
`
`
`Eamonn Gardner
`+1 858 550 6086
`egardner@cooley.com
`
`
`
`
`June 11, 2019
`
`Andrew Danford
`WILMERHALE
`
`Re: Genentech, Inc. et al. v. Amgen, Inc., Case No. 18-924-CFC (D. Del.) – Discovery regarding
`Opinions of Counsel
`
`Counsel,
`
`This letter is in response to your June 3, 2019 correspondence regarding Amgen’s production of certain
`opinions of counsel. While we disagree with numerous characterizations and assertions raised in your
`letter, we write to address Genentech’s various discovery requests.
`
`
` All documents from and correspondence with
`regarding these opinions, including any files from opinion counsel and correspondence
`with opinion counsel. We will produce all communications with Opinion Counsel
`
`
`, and
`any files from Opinion Counsel shared with Amgen.
`
` All underlying documents and drafts of the opinion letter. We will produce all underlying
`documents and drafts of the opinion letters conveyed to Amgen.
`
` All documents relating to the subject matter of these opinion letters, including
`communications with and among any in-house counsel at Amgen, and any other opinions
`or advice of counsel given or received relating to the subject matter. We will produce all
`communications regarding the opinion letters exchanged between Amgen in-house counsel and
`outside opinion counsel and/or Amgen decision-makers who relied upon the opinions, and any
`
`other opinion letters obtained by Amgen
` We will not produce any separate analyses or work product prepared by Amgen’s in-
`house or trial counsel.
`
` Genentech’s request that Amgen withdraw privilege objections to certain requests for
`production, 30(b)(6) topics, and clawed-back documents. Amgen disagrees with any
`suggestion that its production of certain opinions of counsel results in a waiver of all privilege
`objections to the specified RFPs and 30(b)(6) topics. Amgen also disagrees that production of
`certain opinions of counsel somehow waives the separate and unrelated privilege claims for each
`of the clawed-back documents.
`
` Privilege Log. Genentech’s request for a privilege log is unclear. As specified herein, Amgen is
`willing to produce various documents related to Amgen’s reliance on certain opinions of counsel.
`Amgen does not intend to assert any further privilege on those materials. As to any other
`documents, Genentech has no basis for requesting that Amgen provide a privilege log for those
`materials. Moreover, the burden of logging any such materials, especially litigation counsel
`communications, outweighs any benefit here.
`
`
`
`Cooley LLP 4401 Eastgate Mall San Diego, CA 92121
`t: (858) 550-6000 f: (858) 550-6420 cooley.com
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 9 of 39 PageID #: 29244
`
`
`
`June 11, 2019
`Page Two
`
`
` Deposition of
`witnesses.
`
`
`
`
`
`
`
`
`
`. We will propose deposition dates for these
`
` Deposition of Amgen in-house counsel. Amgen will propose deposition dates for one Amgen
`in-house counsel who will provide 30(b)(6) testimony regarding Topic 84 to the extent that topic
`seeks information related to communications with Opinion Counsel.
`
` Depositions of
`
`We disagree with your characterization of the privilege objections made during these depositions;
`Amgen did not instruct any of these witnesses not to answer questions related to opinions of
`counsel. Moreover, we disagree with any suggestion that Amgen’s production of certain opinions
`of counsel waives the privilege issues raised during any of the depositions. Genentech has no
`basis for seeking additional deposition time for these witnesses.
`
` Plaintiff’s 30(b)(6) Topic 84. As stated above, Amgen will provide a witness who will provide
`30(b)(6) testimony regarding the opinion letters relied upon by Amgen.
`
`
`
`Sincerely,
`
`/s/ Eamonn Gardner
`
`Eamonn Gardner
`
`
`
`
`
`205703399
`
`
`
`Cooley LLP 4401 Eastgate Mall San Diego, CA 92121
`t: (858) 550-6000 f: (858) 550-6420 cooley.com
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 10 of 39 PageID #: 29245
`Case 1:18—cv-00924-CFC Document 393 Filed 10/04/19 Page 10 of 39 PageID #: 29245
`
`EXHIBIT 3
`
`EXHIBIT 3
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 11 of 39 PageID #: 29246
`Case 1:18—cv-00924-CFC Doooooot 393 Filed 10/04/19 Page 11 of 39 PageID #: 29246
`
`
`
`THIS DOCUMENT HAS
`THIS DOCUMENT HAS
`
`BEEN REDACTED IN ITS
`BEEN REDACTED IN ITS
`
`ENTIRETY
`
`ENTIRETY
`
`
`
`
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 12 of 39 PageID #: 29247
`Case 1:18—cv-00924-CFC Document 393 Filed 10/04/19 Page 12 of 39 PageID #: 29247
`
`EXHIBIT 4
`
`EXHIBIT 4
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 13 of 39 PageID #: 29248
`
`From:
`To:
`Subject:
`Date:
`
`ded_nefreply@ded.uscourts.gov
`ded_ecf@ded.uscourts.gov
`Activity in Case 1:18-cv-00924-CFC Genentech, Inc. et al v. Amgen Inc. Order on Motion for Miscellaneous Relief
`Thursday, June 20, 2019 8:58:26 AM
`
`This is an automatic e-mail message generated by the CM/ECF system. Please DO NOT
`RESPOND to this e-mail because the mail box is unattended.
`***NOTE TO PUBLIC ACCESS USERS*** Judicial Conference of the United States
`policy permits attorneys of record and parties in a case (including pro se litigants) to
`receive one free electronic copy of all documents filed electronically, if receipt is required
`by law or directed by the filer. PACER access fees apply to all other users. To avoid later
`charges, download a copy of each document during this first viewing. However, if the
`referenced document is a transcript, the free copy and 30 page limit do not apply.
`
`U.S. District Court
`
`District of Delaware
`
`Notice of Electronic Filing
`
`The following transaction was entered on 6/20/2019 at 11:57 AM EDT and filed on 6/20/2019
`Case Name:
`Genentech, Inc. et al v. Amgen Inc.
`Case Number:
`1:18-cv-00924-CFC
`Filer:
`Document Number: 259
`
`Docket Text:
`ORDER granting Plaintiff's Motion to Compel. Signed by Judge Colm F.
`Connolly on 6/20/2019. (nmf)
`
`1:18-cv-00924-CFC Notice has been electronically mailed to:
`
`Neal C. Belgam nbelgam@skjlaw.com, jlayfield@skjlaw.com, kam@skjlaw.com,
`vkm@skjlaw.com
`
`Michael P. Kelly mkelly@mccarter.com, jlano@mccarter.com, tpearson@mccarter.com
`
`Dominick T. Gattuso dgattuso@hegh.law, RMarshall@hegh.law
`
`Orion Armon oarmon@cooley.com
`
`Daniel M. Silver dsilver@mccarter.com, jlano@mccarter.com, kscott@mccarter.com,
`tpearson@mccarter.com
`
`Lisa J. Pirozzolo lisa.pirozzolo@wilmerhale.com, patricia.bessette@wilmerhale.com
`
`Lois M. Kwasigroch loisk@amgen.com
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 14 of 39 PageID #: 29249
`
`Eve H. Ormerod eormerod@skjlaw.com, jlayfield@skjlaw.com, kam@skjlaw.com
`
`Emily R. Whelan emily.whelan@wilmerhale.com
`
`Michelle Rhyu rhyums@cooley.com, cmckinney@cooley.com
`
`Daniel J. Knauss dknauss@cooley.com
`
`Adam R. Brausa abrausa@durietangri.com
`
`Eamonn Gardner egardner@cooley.com
`
`Benjamin S. Lin blin@cooley.com, zAmgenGenentech@cooley.com
`
`Timothy Cook tim.cook@wilmerhale.com
`
`Brian Kao bkao@amgen.com
`
`Teagan J. Gregory tgregory@wc.com
`
`Susan Krumplitsch skrumplitsch@cooley.com, tgibbs@cooley.com
`
`Nancy L. Schroeder nancy.schroeder@wilmerhale.com, vickie.carrillo@wilmerhale.com
`
`Jennifer M. Rutter jrutter@skjlaw.com
`
`Jason H. Liss jason.liss@wilmerhale.com
`
`Philip H. Mao pmao@cooley.com, tgibbs@cooley.com
`
`Alexandra M. Joyce ajoyce@mccarter.com, jlano@mccarter.com
`
`Nancy J. Gettel ngettel@amgen.com
`
`Rana Sawaya rana.sawaya@wilmerhale.com
`
`Mark D. McBriar mark.mcbriar@wilmerhale.com
`
`Alexandra Leeper aleeper@cooley.com
`
`Alissa M. Wood amwood@cooley.com
`
`Lauren Krickl lkrickl@cooley.com
`
`Helena Million-Perez rachael.million-perez@wilmerhale.com
`
`Xiaoxiao Xue xxue@cooley.com
`
`1:18-cv-00924-CFC Filer will deliver document by other means to:
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 15 of 39 PageID #: 29250
`
`The following document(s) are associated with this transaction:
`Document description:Main Document
`Original filename:n/a
`Electronic document Stamp:
`[STAMP dcecfStamp_ID=1079733196 [Date=6/20/2019] [FileNumber=3863740-0
`] [1c7de7be81dc51bccf99cb816a891648d008ae90f895b888ccaa4a24944e12e9808
`bd399afcf378245b9f6900e67ea43c02818f3ac193ae3e218605aaa3f5084]]
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 16 of 39 PageID #: 29251
`Case 1:18—cv-00924-CFC Document 393 Filed 10/04/19 Page 16 of 39 PageID #: 29251
`
`EXHIBIT 5
`
`EXHIBIT 5
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 17 of 39 PageID #: 29252
`
`From:
`To:
`Subject:
`Date:
`
`ded_nefreply@ded.uscourts.gov
`ded_ecf@ded.uscourts.gov
`Activity in Case . Genentech, Inc. v. Amgen Inc. Memorandum and Order
`Wednesday, August 28, 2019 6:13:33 AM
`
`This is an automatic e-mail message generated by the CM/ECF system. Please DO NOT
`RESPOND to this e-mail because the mail box is unattended.
`***NOTE TO PUBLIC ACCESS USERS*** There is no charge for viewing opinions.
`
`U.S. District Court
`
`District of Delaware
`
`Notice of Electronic Filing
`
`The following transaction was entered on 8/28/2019 at 9:11 AM EDT and filed on 8/28/2019
`Case Name:
`Genentech, Inc. et al v. Amgen Inc.
`Case Number:
`1:17-cv-01407-CFC
`Filer:
`Document Number: 488
`
`Docket Text:
`MEMORANDUM ORDER denying (266 in 1:18-cv-00924-CFC) MOTION for
`Reargument filed by Amgen Inc., denying (423 in 1:17-cv-01407-CFC) MOTION
`for Reargument re (407) Order filed by Amgen Inc. Amgen shall file the
`privileged documents no later than September 4, 2019. Signed by Judge Colm
`F. Connolly on 8/28/2019. (nmf)
`Case Name:
`Case Number:
`Filer:
`Document Number: 345
`
`Genentech, Inc. v. Amgen Inc.
`1:18-cv-00924-CFC
`
`Docket Text:
`MEMORANDUM ORDER denying (266 in 1:18-cv-00924-CFC) MOTION for
`Reargument filed by Amgen Inc., denying (423 in 1:17-cv-01407-CFC) MOTION
`for Reargument re (407) Order filed by Amgen Inc. Amgen shall file the
`privileged documents no later than September 4, 2019. Signed by Judge Colm
`F. Connolly on 8/28/2019. (nmf)
`
`1:17-cv-01407-CFC Notice has been electronically mailed to:
`
`Michael P. Kelly mkelly@mccarter.com, jlano@mccarter.com, tpearson@mccarter.com
`
`Melanie K. Sharp msharp@ycst.com, achataikin@ycst.com, asmit@ycst.com,
`mgassaway@ycst.com
`
`Dominick T. Gattuso dgattuso@hegh.law, RMarshall@hegh.law
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 18 of 39 PageID #: 29253
`
`James Michael Lennon jlennon@devlinlawfirm.com, ecfdocketing@devlinlawfirm.com,
`ehunt@rmmslegal.com, fxu@devlinlawfirm.com, mmcclain@devlinlawfirm.com
`
`Steven M. Bauer sbauer@proskauer.com, cdeck@proskauer.com
`
`Kimberly A. Mottley kmottley@proskauer.com, kimberly-mottley-1551@ecf.pacerpro.com
`
`Amir A. Naini anaini@proskauer.com, amir-naini-2159@ecf.pacerpro.com
`
`Daniel M. Silver dsilver@mccarter.com, jlano@mccarter.com, kford@mccarter.com,
`tpearson@mccarter.com
`
`David I. Berl dberl@wc.com
`
`Daralyn J. Durie ddurie@durietangri.com
`
`James L. Higgins jhiggins@ycst.com, achataikin@ycst.com, asmit@ycst.com,
`corpcal@ycst.com, corporate@ycst.com
`
`Siegmund Y. Gutman sgutman@proskauer.com, sigemund-gutman-
`5494@ecf.pacerpro.com
`
`Benjamin A. Smyth bsmyth@mccarter.com
`
`Adam R. Brausa abrausa@durietangri.com
`
`Gourdin W. Sirles gsirles@proskauer.com, gourdin-sirles-6609@ecf.pacerpro.com
`
`Brian Kao bkao@amgen.com
`
`Teagan J. Gregory tgregory@wc.com
`
`Thomas S. Fletcher tfletcher@wc.com
`
`David M. Hanna dhanna@proskauer.com
`
`D. Shayon Ghosh sghosh@wc.com
`
`Kyle E. Thomason kthomason@wc.com
`
`Jonathan S. Sidhu jsidhu@wc.com
`
`Alexandra M. Joyce ajoyce@mccarter.com, jlano@mccarter.com
`
`Eneda Hoxha ehoxha@durietangri.com
`
`Michelle M. Ovanesian movanesian@proskauer.com
`
`Charles L. McCloud lmccloud@wc.com
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 19 of 39 PageID #: 29254
`
`Nancy J. Gettel ngettel@amgen.com
`
`Sumeet P. Dang sdang@wc.com
`
`Jingyuan Luo jluo@wc.com
`
`Eric C. Wiener ewiener@durietangri.com
`
`Kimberly Q. Li kli@proskauer.com
`
`J. Drew Diamond ddiamond@amgen.com
`
`Sarah M. Harris sharris@wc.com
`
`1:17-cv-01407-CFC Filer will deliver document by other means to:
`
`1:18-cv-00924-CFC Notice has been electronically mailed to:
`
`Neal C. Belgam nbelgam@skjlaw.com, jlayfield@skjlaw.com, kam@skjlaw.com,
`vkm@skjlaw.com
`
`Michael P. Kelly (Terminated) mkelly@mccarter.com, jlano@mccarter.com,
`tpearson@mccarter.com
`
`Dominick T. Gattuso dgattuso@hegh.law, RMarshall@hegh.law
`
`Orion Armon oarmon@cooley.com
`
`Amir A. Naini anaini@proskauer.com, amir-naini-2159@ecf.pacerpro.com
`
`Daniel M. Silver (Terminated) dsilver@mccarter.com, jlano@mccarter.com,
`kford@mccarter.com, tpearson@mccarter.com
`
`Lisa J. Pirozzolo lisa.pirozzolo@wilmerhale.com, patricia.bessette@wilmerhale.com
`
`Siegmund Y. Gutman sgutman@proskauer.com, sigemund-gutman-
`5494@ecf.pacerpro.com
`
`Lois M. Kwasigroch loisk@amgen.com
`
`Eve H. Ormerod eormerod@skjlaw.com, jlayfield@skjlaw.com, kam@skjlaw.com
`
`Emily R. Whelan (Terminated) emily.whelan@wilmerhale.com
`
`Michelle Rhyu rhyums@cooley.com, cmckinney@cooley.com
`
`Daniel J. Knauss dknauss@cooley.com
`
`Adam R. Brausa (Terminated) abrausa@durietangri.com
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 20 of 39 PageID #: 29255
`
`Andrew J. Danford andrew.danford@wilmerhale.com
`
`Eamonn Gardner egardner@cooley.com
`
`Benjamin S. Lin blin@cooley.com, zAmgenGenentech@cooley.com
`
`Timothy Cook tim.cook@wilmerhale.com
`
`Brian Kao bkao@amgen.com
`
`Teagan J. Gregory tgregory@wc.com
`
`Susan Krumplitsch skrumplitsch@cooley.com, tgibbs@cooley.com
`
`Nancy L. Schroeder (Terminated) nancy.schroeder@wilmerhale.com,
`vickie.carrillo@wilmerhale.com
`
`David M. Hanna dhanna@proskauer.com
`
`Jennifer M. Rutter jrutter@skjlaw.com
`
`Jason H. Liss (Terminated) jason.liss@wilmerhale.com
`
`Philip H. Mao pmao@cooley.com, tgibbs@cooley.com
`
`Alexandra M. Joyce (Terminated) ajoyce@mccarter.com, jlano@mccarter.com
`
`Nancy J. Gettel ngettel@amgen.com
`
`Rana Sawaya rana.sawaya@wilmerhale.com
`
`Mark D. McBriar (Terminated) mark.mcbriar@wilmerhale.com
`
`Alexandra Leeper aleeper@cooley.com
`
`Alissa M. Wood amwood@cooley.com
`
`Lauren Krickl lkrickl@cooley.com
`
`Helena Million-Perez (Terminated) rachael.million-perez@wilmerhale.com
`
`Xiaoxiao Xue xxue@cooley.com
`
`1:18-cv-00924-CFC Filer will deliver document by other means to:
`
`The following document(s) are associated with this transaction:
`Document description:Main Document
`Original filename:n/a
`Electronic document Stamp:
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 21 of 39 PageID #: 29256
`
`[STAMP dcecfStamp_ID=1079733196 [Date=8/28/2019] [FileNumber=3926849-0
`] [ca0d715806249d93746479ee72a0fed01097537ec83c807b04d578dacf304fb2e10
`726fe99d5bc09013bfa79383322c3bf8287513d226966ee528b19a5682953]]
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 22 of 39 PageID #: 29257
`Case 1:18—cv-00924-CFC Document 393 Filed 10/04/19 Page 22 of 39 PageID #: 29257
`
`EXHIBIT 6
`
`EXHIBIT 6
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 23 of 39 PageID #: 29258
`Case 1:18-CV-00924-CFC Doooooot 393 Filed 10/04/19 Page 23 of 39 PageID #: 29258
`
`
`
`THIS DOCUMENT HAS
`THIS DOCUMENT HAS
`
`BEEN REDACTED IN ITS
`BEEN REDACTED IN ITS
`
`ENTIRETY
`
`ENTIRETY
`
`
`
`
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 24 of 39 PageID #: 29259
`Case 1:18—cv-00924-CFC Document 393 Filed 10/04/19 Page 24 of 39 PageID #: 29259
`
`EXHIBIT 7
`
`EXHIBIT 7
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 25 of 39 PageID #: 29260
`Case 1:18-CV-00924-CFC Doooooot 393 Filed 10/04/19 Page 25 of 39 PageID #: 29260
`
`
`
`THIS DOCUMENT HAS
`THIS DOCUMENT HAS
`
`BEEN REDACTED IN ITS
`BEEN REDACTED IN ITS
`
`ENTIRETY
`
`ENTIRETY
`
`
`
`
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 26 of 39 PageID #: 29261
`Case 1:18—cv-00924-CFC Document 393 Filed 10/04/19 Page 26 of 39 PageID #: 29261
`
`EXHIBIT 8
`
`EXHIBIT 8
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 27 of 39 PageID #: 29262
`Case 1:18—cv-00924-CFC Doooooot 393 Filed 10/04/19 Page 27 of 39 PageID #: 29262
`
`
`
`THIS DOCUMENT HAS
`THIS DOCUMENT HAS
`
`BEEN REDACTED IN ITS
`BEEN REDACTED IN ITS
`
`ENTIRETY
`
`ENTIRETY
`
`
`
`
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 28 of 39 PageID #: 29263
`Case 1:18—cv-00924-CFC Document 393 Filed 10/04/19 Page 28 of 39 PageID #: 29263
`
`EXHIBIT 9
`
`EXHIBIT 9
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 29 of 39 PageID #: 29264
`Case 1:18—cv-00924-CFC Doooooot 393 Filed 10/04/19 Page 29 of 39 PageID #: 29264
`
`
`
`THIS DOCUMENT HAS
`THIS DOCUMENT HAS
`
`BEEN REDACTED IN ITS
`BEEN REDACTED IN ITS
`
`ENTIRETY
`
`ENTIRETY
`
`
`
`
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 30 of 39 PageID #: 29265
`Case 1:18—cv-00924-CFC Document 393 Filed 10/04/19 Page 30 of 39 PageID #: 29265
`
`EXHIBIT 10
`
`EXHIBIT 10
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 31 of 39 PageID #: 29266
`Case 1:18-CV-00924-CFC Doooooot 393 Filed 10/04/19 Page 31 of 39 PageID #: 29266
`
`
`
`THIS DOCUMENT HAS
`THIS DOCUMENT HAS
`
`BEEN REDACTED IN ITS
`BEEN REDACTED IN ITS
`
`ENTIRETY
`
`ENTIRETY
`
`
`
`
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 32 of 39 PageID #: 29267
`Case 1:18—cv-00924-CFC Document 393 Filed 10/04/19 Page 32 of 39 PageID #: 29267
`
`EXHIBIT 11
`
`EXHIBIT 11
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 33 of 39 PageID #: 29268
`Case 1:18-CV-00924-CFC Doooooot 393 Filed 10/04/19 Page 33 of 39 PageID #: 29268
`
`
`
`THIS DOCUMENT HAS
`THIS DOCUMENT HAS
`
`BEEN REDACTED IN ITS
`BEEN REDACTED IN ITS
`
`ENTIRETY
`
`ENTIRETY
`
`
`
`
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 34 of 39 PageID #: 29269
`Case 1:18—cv-00924-CFC Document 393 Filed 10/04/19 Page 34 of 39 PageID #: 29269
`
`EXHIBIT 12
`
`EXHIBIT 12
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 35 of 39 PageID #: 29270
`Case 1:18-CV-00924-CFC Doooooot 393 Filed 10/04/19 Page 35 of 39 PageID #: 29270
`
`
`
`THIS DOCUMENT HAS
`THIS DOCUMENT HAS
`
`BEEN REDACTED IN ITS
`BEEN REDACTED IN ITS
`
`ENTIRETY
`
`ENTIRETY
`
`
`
`
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 36 of 39 PageID #: 29271
`Case 1:18—cv-00924-CFC Document 393 Filed 10/04/19 Page 36 of 39 PageID #: 29271
`
`EXHIBIT 13
`
`EXHIBIT 13
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 37 of 39 PageID #: 29272
`Case 1:18—cv-00924-CFC Doooooot 393 Filed 10/04/19 Page 37 of 39 PageID #: 29272
`
`
`
`THIS DOCUMENT HAS
`THIS DOCUMENT HAS
`
`BEEN REDACTED IN ITS
`BEEN REDACTED IN ITS
`
`ENTIRETY
`
`ENTIRETY
`
`
`
`
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 38 of 39 PageID #: 29273
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned counsel hereby certifies that true and correct copies of the foregoing
`
`document were caused to be served on September 24, 2019 on the following counsel in the
`
`manner indicated:
`
`
`VIA EMAIL:
`
`Neal C. Belgam
`Eve H. Ormerod
`Jennifer M. Rutter
`SMITH, KATZENSTEIN & JENKINS, LLP
`1000 West Street, Suite 1501
`Wilmington, DE 19801
`(302) 652-8400
`nbelgam@skjlaw.com
`eormerod@skjlaw.com
`jrutter@skjlaw.com
`
`
`Orion Armon
`COOLEY, LLP
`380 Interlocken Crescent, Suite 900
`Broomfield, CO 80021-8023
`(720) 566-4119
`oarmon@cooley.com
`
`
`Eamonn Gardner
`COOLEY, LLP
`4401 Eastgate Mall
`San Diego, CA 92121-1909
`(858) 550-6086
`egardner@cooley.com
`
`
`
`
`
`
`
`
`
`
`
`ME1 31544755v.1
`
`

`

`Case 1:18-cv-00924-CFC Document 393 Filed 10/04/19 Page 39 of 39 PageID #: 29274
`
`
`
`Michelle Rhyu
`Susan Krumplitsch
`Daniel Knauss
`Philip H. Mao
`Alexandra Leeper
`Lauren Krickl
`Benjamin S. Lin
`Alissa M. Wood
`COOLEY, LLP
`3175 Hanover Street
`Palo Alto, CA 94304-1130
`(650) 843-5287
`rhyums@cooley.com
`skrumplitsch@cooley.com
`dknauss@cooley.com
`pmao@cooley.com
`aleeper@cooley.com
`lkrickl@cooley.com
`blin@cooley.com
`amwood@cooley.com
`
`Nancy Gettel
`Brian Kao
`Lois Kwasigroch
`AMGEN, INC.
`One Amgen Center Drive
`Thousand Oaks, CA 91320-1799
`(805) 447-1000
`ngettel@amgen.com
`bkao@amgen.com
`loisk@amgen.com
`
`Xiaoxiao Xue
`1299 Pennsylvania Avenue, NW, Suite 700
`Washington, DC 20004-2400
`(202) 842-7809
`xxue@cooley.com
`
`Attorneys for Defendant Amgen Inc.
`
`
`
`Dated: September 24, 2019
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/s/ Daniel M. Silver
`Daniel M. Silver (#4758)
`
`
`
`
`
`
`ME1 31544755v.1
`
`2
`
`